At what enterprise value was CIRION BIOPHARMA RESEARCH acquired in 2023?

You can find the full valuation details of CIRION BIOPHARMA RESEARCH on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CIRION BIOPHARMA RESEARCH when it was acquired by CERBA HEALTHCARE?

The exact EV/EBITDA multiple for CIRION BIOPHARMA RESEARCH is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of CIRION BIOPHARMA RESEARCH at the time of the deal?

The revenue of CIRION BIOPHARMA RESEARCH at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CIRION BIOPHARMA RESEARCH acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CIRION BIOPHARMA RESEARCH deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/build-up/cerba-healthcare-simplante-au-canada-1977900

← DATABASE

Home Database Healthcare & PharmaCIRION BIOPHARMA RESEARCH

09/2023

CIRION BIOPHARMA RESEARCH acquired by CERBA HEALTHCARE

CANADA Healthcare Services / CRO / Clinical Trials REV 5M - 25M EUR

Context

Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs. The transaction followed Cerba's previous major international acquisitions of Lifebrain (Italy) and Viroclinics-DDL (Netherlands), furthering the global expansion strategy initiated under EQT's majority ownership since 2021.

By taking control of Cirion Biopharma Research, Cerba Healthcare continues its expansion strategy. Previously, the group had completed 3 acquisitions, including Labexa in 2021.

CIRION BIOPHARMA RESEARCH, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Cirion is a premier Canadian Contract Research Organization (CRO) specializing in bioanalytical laboratory services for the pharmaceutical and biotechnology industries. The company provides integrated support across the entire drug development lifecycle, from preclinical research to Phase III clinical trials. Key areas of expertise include Pharmacokinetics/Pharmacodynamics (PKPD) assay development, immunogenicity testing, and large molecule analysis. Cirion operates a state-of-the-art facility in Laval that is fully compliant with GLP (Good Laboratory Practice) and North American regulatory standards (FDA/Health Canada), serving a global client base that includes several of the world's top 10 pharmaceutical companies. The team consists of over 80 highly skilled professionals, including PhD holders and medical specialists.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	Healthcare Services	Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	Healthcare Services	Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Healthcare Services	Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services	Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization
11/2020	KERSIA	SOPURA	BELGIUM	Healthcare Services	Kersia acquired 100% of Sopura from its shareholders as part of a strategic build-up program. This transaction was integrated into a larger financing package arranged during the acquirer's own ownership transition to a new private equity sponsor
10/2020	IK PARTNERS	KERSIA	FRANCE	Healthcare Services	IK Investment Partners acquired a majority stake in Kersia from Ardian. This transaction was initiated through exclusive negotiations via the IK IX fund, marking the first deal for this specific vehicle
05/2020	CLAYTON, DUBILIER & RICE (CD&R)	HUNTSWORTH	UNITED KINGDOM	Healthcare Services	Clayton, Dubilier & Rice, LLC completed its acquisition of Huntsworth PLC on May 1, 2020. The strategic rationale centers on Huntsworth’s position as a leading pharma commercialization services platform, with a strong Health division contributing roughly 85% of the group’s operating profit
01/2018	SPECTRIS	CONCEPT LIFE SCIENCES	UNITED KINGDOM	Healthcare Services	Spectris plc has successfully finalized the acquisition of 100% of the share capital of the target from a mid-market private equity firm. This strategic transaction represents a definitive step in the group’s evolution toward a combined product-and-service proposition within its specialized materials analysis segment
04/2016	CHARLES RIVER LABORATORIES	WIL RESEARCH	UNITED STATES	Healthcare Services	Charles River Laboratories has finalized the acquisition of WIL Research from a shareholder group led by American Capital, Ltd. and The Wicks Group. The strategic rationale for this transaction centers on a "service-continuum" play, merging the target's technical operational depth in specialty safety assessment and CDMO services with the group's established global contract research infrastructure

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CIRION BIOPHARMA RESEARCH by CERBA HEALTHCARE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: cerba healthcare